Drug Development

With a $50M seed round, Radical Numerics aims to build general biological intelligence, walking a fine line between curing disease and creating bioweapons.

Sumitomo Pharma's new data reveals a potent combination therapy for myelofibrosis and decodes resistance in leukemia, shaking up a competitive oncology landscape.

New data reveals elevated cortisol in over 75% of hard-to-treat diabetes patients, paving the way for a novel drug to tackle treatment resistance.

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.

While CEO Craig Chambliss's EY award makes headlines, the real story is Neurelis's disruption of epilepsy care and its ambitious pipeline for brain disorders.

With a landmark therapy for Sanfilippo Syndrome nearing the FDA, Spruce adds veteran marketing and finance chiefs. A look at the talent behind the transition.

As 250 million people await a drug for lymphatic diseases, Celltaxis appoints a new CEO to drive its promising inflammation-targeting therapy toward the finish line.

The deal showcases a masterful exit in a tough market and signals deeper shifts in the pharma R&D landscape, where specialized research partners are king.

Tiziana Life Sciences’ chairman just increased his massive stake. We analyze if this is a vote of confidence in its novel MS drug or a risky bet on a fragile biotech.

New data reveals an oral drug can halt severe hereditary angioedema attacks in minutes, promising a future free from needles and fear for thousands.

China's Atom Therapeutics is advancing a dual-threat pipeline, with novel drugs for gout and a groundbreaking anti-inflammatory aimed at cardiovascular disease.

While biopharma braces for Medicare price negotiations, Halozyme claims immunity. Is its tech-licensing model the new blueprint for resilience or just a loophole?

With UK approval for its EURneffy 1 mg nasal spray, ALK is set to disrupt the pediatric anaphylaxis market by offering a game-changing needle-free alternative.

Akeso's new breast cancer trial is more than a clinical step; it's a key move in a bold strategy to dominate next-gen cancer therapy and capture a lucrative market.

Stunning new US/EU data for BTK inhibitor orelabrutinib signals a major push into Western markets, challenging established blood cancer therapies.

A Dutch biotech is in late-stage trials for nizubaglustat, a drug targeting rare, fatal neurological disorders. A look at the science, strategy, and hope.

New data shows remarkable response rates for epcoritamab in a vulnerable patient group with limited options, signaling a potential paradigm shift in first-line lymphoma care.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

Promising clinical trial results offer hope for cancer patients at risk of permanent, treatment-induced hearing loss, a devastating and common trade-off.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.